References
- Ansiaux R, Baudelet C, Jordon BF, et al (2005). Thalidomide radiosensitises tumors through early changes in the tumor microenviroment. Clin Cancer Res, 11, 743-50.
- Bartlett JB, Dredge K, Dalgleish AG et al (2004). The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer, 4, 314-22. https://doi.org/10.1038/nrc1323
- Battegay EJ (1995). Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med (Berl), 73, 333-46.
- Carmeliet P, Ferreira V, Breier G, et al (1996). Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature, 380, 435-9. https://doi.org/10.1038/380435a0
- Cui L, Liu XX, Jiang Y, et al (2014). Phase II study on dose escalating schedule of paclitaxel concurrent with radiotherapy in treating patients with locally advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 15, 1699-702. https://doi.org/10.7314/APJCP.2014.15.4.1699
- D'Amato RJ, Loughnan MS, Flynn E, et al (1994). Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA, 91, 4082-5. https://doi.org/10.1073/pnas.91.9.4082
- Ferrara N (1999). Molecular and biological properties of vascular endothelial growth factor. J Mol Med, 77, 527-43. https://doi.org/10.1007/s001099900019
- Folkman J (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med, 1, 27-31. https://doi.org/10.1038/nm0195-27
- Fujita J, Mestre JR, Zeldis JB, et al (2001). Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of -2. Clin Cancer Res, 7, 3349-55.
- Geitz H, Handt S, Zwingenberger K (1996). Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology, 31, 213-21. https://doi.org/10.1016/0162-3109(95)00050-X
- Gerber HP, Hillan KJ, Ryan AM, et al (1999). VEGF is required for growth and survival in neonatal mice. Development, 126, 1149-59.
- Govindan R, Page N , Morgensztern D, et al (2006). Changing epidemiology of small-cell lung cancer in the United States over the last 30years:analysisoftheSurveillance, Epidemiologic, and End Results database. J Clin Oncol, 24, 4539-44. https://doi.org/10.1200/JCO.2005.04.4859
- Hanahan D, Weinberg RA (2000).The hallmarks of cancer. Cell, 100, 57-70. https://doi.org/10.1016/S0092-8674(00)81683-9
- Haslett PA, Corral LG, Albert M, et al (1998). Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med, 187, 1885-92. https://doi.org/10.1084/jem.187.11.1885
- Huang XE, Wang L, Ji ZQ, et al (2015). Safety of Lienal Polypeptide Injection Combined with Chemotherapy in Treating Patients with Advanced Cancer. Asian Pac J Cancer Prev, 16, 7837-41. https://doi.org/10.7314/APJCP.2015.16.17.7837
- Huang XE, Tian GY, Cao J, et al (2014). Pemetrexed as a component of first-, second- and third- line chemotherapy in treating patients with metastatic lung adenocarcinoma. Asian Pac J Cancer Prev, 14, 6663-7.
- Jain RK (2001) .Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med, 7, 987-9. https://doi.org/10.1038/nm0901-987
- Jain RK (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 307, 58-62. https://doi.org/10.1126/science.1104819
- Jemal A, MurrayT, WardE, et al (2005). Cancer statistics. CA Cancer J Clin, 55, 10-30. https://doi.org/10.3322/canjclin.55.1.10
- Ji ZQ, Huang XE, Wu XY, et al (2014). Safety of Brucea javanica and cantharidin combined with chemotherapy for treatment of NSCLC patients. Asian Pac J Cancer Prev, 15, 8603-5. https://doi.org/10.7314/APJCP.2014.15.20.8603
- Jin SH, Kim TI, Han DS, et al (2002). Thalidomide suppresses the interleukin 1beta-induced NFkappaB signaling pathway in colon cancer cells. Ann NY Acad Sci, 973, 414-8. https://doi.org/10.1111/j.1749-6632.2002.tb04674.x
- Keifer JA, Guttridge DC, Ashburner BP, et al (2001). Inhibition of NF-kappa B activity by thalidomidethrough suppression of IkappaB kinase activity. J Biol Chem, 276, 22382-7. https://doi.org/10.1074/jbc.M100938200
- Li Y, Huang XE (2015). A Pooled Analysis on Crizotinib in Treating Chinese Patients with EML4-ALK Positive Non-small-cell Lung Cancer. Asian Pac J Cancer Prev, 16, 4797-800. https://doi.org/10.7314/APJCP.2015.16.11.4797
- Mall JW, Philipp AW, Mall W, Pollmann C (2002). Long-term survival of a patient with small-cell lung cancer :SCLC: following treatment with thalidomide and combination chemotherapy. Angiogenesis, 5, 11-3. https://doi.org/10.1023/A:1021546630577
- Prat A, Casado E, Cortes J (2007). New approaches in angiogenic targeting for colorectal cancer. World J Gastroenterol, 13, 5857-66. https://doi.org/10.3748/wjg.v13.i44.5857
- Plate KH, Breier G, Weich HA, et al (1992). Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature, 359, 845-8. https://doi.org/10.1038/359845a0
- Segers J, Fazio VD , Ansiaux R, et al (2006). Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic agent thalidomide:importance of optimal scheduling to exploit the 'normalization 'window of the tumor vasculature. Cancer Lett, 244, 129-35. https://doi.org/10.1016/j.canlet.2005.12.017
- Shi B, Zhang XB, Xu J, et al (2015). Systematic Analysis of Icotinib Treatment for Patients with Non-Small Cell Lung Cancer. Asian Pac J Cancer Prev, 16, 5521-4. https://doi.org/10.7314/APJCP.2015.16.13.5521
- Shweiki D, Itin A, Soffer D, et al (1992). Vascular endothelial growth factor induced by hypoxia may mediate hypoxiainitiated angiogenesis. Nature, 359, 843-5. https://doi.org/10.1038/359843a0
- Vasvari GP, Dyckhoff G, Kashfi F, et al (2007). Combination of thalidomide and cisplatin in an head and neck squamous cell carcinomas model results in an enhanced antiangiogenic activity in vitro and in vivo. Int J Cancer, 121, 1697-704. https://doi.org/10.1002/ijc.22867
- Veikkola T, Karkkainen M, Claesson-Welsh L, et al (2000). Regulation of angiogenesis via vascular endothelial growth 7870 Asian Pacific Journal of Cancer Prevention, Vol 16, 2015 factor receptors. Cancer Res, 60, 203-12.
- Wu XY, Huang XE (2015). Screening for patients with non-small cell lung cancer who could survive long term chemotherapy. Asian Pac J Cancer Prev, 16, 647-52. https://doi.org/10.7314/APJCP.2015.16.2.647